Caris Life Sciences, Inc. (CAI) Cash Flow Statement

The gap between net income and operating cash flow is large and inconsistent in direction, with several quarters showing positive OCF alongside losses and others showing negative OCF alongside profits. This pattern suggests that working capital timing, non-cash charges such as stock-based compensation and depreciation, and revenue recognition on billed-but-unpaid claims may be materially distorting the reconciliation. Investors should treat the OCF trend, rather than any single quarter's ratio, as the more reliable indicator of underlying cash conversion while the earnings base remains unstable.

The free cash flow trajectory is non-monotonic, with a 25.5% FCF margin in 2025Q3 followed by a sharp reversal driven largely by a $67.6M working capital outflow in the most recent quarter. This suggests the earlier positive FCF may have reflected timing benefits rather than durable margin improvement. Until FCF margins stabilize across several consecutive quarters, the cash generation profile warrants monitoring rather than extrapolation.

The magnitude of working capital movements relative to operating cash flow is large, implying that collections timing on reimbursement-driven clinical revenue likely plays a central role. The most recent outflow may reflect receivable build-up tied to rapid volume growth, which would be consistent with the 27% year-over-year revenue expansion but also raises questions about collection efficiency. Investors should monitor days sales outstanding for signs of whether growth is converting to cash.

Recent capex runs between roughly 1.7% and 12.3% of revenue, which appears modest relative to a laboratory-based diagnostics model but may understate reinvestment needs as sequencing volume scales. The 2021 outlier of $545.2M suggests a major facility or equipment program that is not representative of current run-rate spending. Whether recent capex levels are sufficient to support the sequencing capacity implied by 61,500 quarterly cases remains an open question the data cannot resolve.

Because net income and operating cash flow diverge in both sign and magnitude across the available periods, a cumulative reconciliation does not produce a clear conclusion about earnings quality. The data suggests non-cash charges and working capital timing are doing most of the reconciling work. Investors should await a longer run of consistent profitability before drawing firm conclusions about whether reported losses represent a cash burn or an accounting artifact.